Stryker Corporation $SYK Stock Position Lowered by Sumitomo Mitsui Trust Group Inc.

Sumitomo Mitsui Trust Group Inc. decreased its position in Stryker Corporation (NYSE:SYK) by 5.0% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 774,276 shares of the medical technology company’s stock after selling 40,695 shares during the quarter. Sumitomo Mitsui Trust Group Inc.’s holdings in Stryker were worth $254,419,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently bought and sold shares of the company. Czech National Bank lifted its holdings in shares of Stryker by 3.9% during the fourth quarter. Czech National Bank now owns 90,755 shares of the medical technology company’s stock valued at $31,898,000 after purchasing an additional 3,366 shares during the last quarter. Kepler Cheuvreux Suisse SA purchased a new position in Stryker in the 3rd quarter worth about $27,952,000. Daymark Wealth Partners LLC raised its holdings in Stryker by 436.0% during the 4th quarter. Daymark Wealth Partners LLC now owns 45,863 shares of the medical technology company’s stock worth $16,119,000 after buying an additional 37,307 shares during the period. Varma Mutual Pension Insurance Co raised its holdings in Stryker by 10.5% during the 4th quarter. Varma Mutual Pension Insurance Co now owns 53,610 shares of the medical technology company’s stock worth $18,842,000 after buying an additional 5,100 shares during the period. Finally, Wealthcare Advisory Partners LLC lifted its stake in Stryker by 265.2% during the fourth quarter. Wealthcare Advisory Partners LLC now owns 9,328 shares of the medical technology company’s stock valued at $3,278,000 after buying an additional 6,774 shares in the last quarter. 77.09% of the stock is owned by institutional investors and hedge funds.

Stryker Trading Down 0.8%

NYSE:SYK opened at $327.17 on Thursday. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.11 and a quick ratio of 1.25. Stryker Corporation has a fifty-two week low of $281.00 and a fifty-two week high of $404.87. The stock’s 50-day moving average is $309.71 and its two-hundred day moving average is $338.22. The stock has a market cap of $125.42 billion, a PE ratio of 37.87, a price-to-earnings-growth ratio of 2.11 and a beta of 0.77.

Stryker (NYSE:SYK) last issued its earnings results on Thursday, April 30th. The medical technology company reported $2.60 earnings per share for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). The business had revenue of $6.02 billion during the quarter, compared to analyst estimates of $6.34 billion. Stryker had a net margin of 13.20% and a return on equity of 23.42%. Stryker’s revenue for the quarter was up 2.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.84 EPS. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. As a group, equities research analysts forecast that Stryker Corporation will post 14.98 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Tuesday, June 30th will be paid a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 1.1%. The ex-dividend date is Tuesday, June 30th. Stryker’s dividend payout ratio is currently 40.74%.

Insiders Place Their Bets

In other Stryker news, VP Robert S. Fletcher sold 4,544 shares of Stryker stock in a transaction on Thursday, May 28th. The shares were sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the completion of the sale, the vice president owned 10,582 shares of the company’s stock, valued at $3,247,298.34. This trade represents a 30.04% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Ronda E. Stryker sold 310,000 shares of Stryker stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total transaction of $96,791,300.00. Following the sale, the director directly owned 1,924,880 shares of the company’s stock, valued at $601,005,282.40. This trade represents a 13.87% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 323,264 shares of company stock worth $100,659,489 in the last quarter. 4.60% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several research analysts have recently weighed in on SYK shares. Truist Financial reissued a “hold” rating and issued a $330.00 target price (down from $380.00) on shares of Stryker in a research report on Monday, May 4th. UBS Group reduced their price target on shares of Stryker from $400.00 to $380.00 and set a “neutral” rating for the company in a research report on Tuesday, March 17th. Robert W. Baird set a $385.00 price objective on shares of Stryker in a research note on Friday, May 1st. Wells Fargo & Company lowered their price objective on shares of Stryker from $456.00 to $418.00 and set an “overweight” rating on the stock in a research report on Friday, May 1st. Finally, Evercore set a $350.00 target price on shares of Stryker in a research note on Monday. Seventeen research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $393.91.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.